Evaluation of SureCore Plus Biopsy System

Launched by URO-1 MEDICAL · Aug 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new biopsy system called the SureCore Plus, which is used to take tissue samples from the prostate in men with benign prostatic hyperplasia (BPH), a condition that causes an enlarged prostate. The goal is to see if this new system can provide better quality and larger tissue samples compared to the standard biopsy needles currently used. This is important because the quality of the tissue samples can affect how well doctors can diagnose and treat patients.

To participate in this study, men aged 65 to 74 who have BPH and need a prostate biopsy can enroll if they are willing to give their consent. However, those with an active infection or who are already part of another study involving prostate devices cannot join. Participants in the trial will receive the SureCore Plus biopsy and will help researchers understand if this new system can improve the biopsy process. The study is not yet recruiting, so interested individuals should keep an eye out for updates.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patient has BPH requiring a prostate biopsy
• • Able and willing to provide consent
• Exclusion Criteria:
• • Active infection
• • Subject participating in an other device study of the prostate